ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Update

ABIVAX Société Anonyme (NASDAQ:ABVX) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 96,500 shares, an increase of 68.7% from the July 15th total of 57,200 shares. Based on an average trading volume of 65,900 shares, the days-to-cover ratio is currently 1.5 days. Currently, 0.2% of the shares of the stock are sold short.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Laidlaw started coverage on shares of ABIVAX Société Anonyme in a research report on Monday, July 29th. They set a “buy” rating and a $48.00 price target on the stock. Guggenheim assumed coverage on shares of ABIVAX Société Anonyme in a report on Monday, April 29th. They set a “buy” rating and a $50.00 target price on the stock. Piper Sandler assumed coverage on shares of ABIVAX Société Anonyme in a research note on Monday, April 29th. They issued an “overweight” rating and a $42.00 price target for the company. Finally, BTIG Research started coverage on ABIVAX Société Anonyme in a research note on Monday, May 20th. They set a “buy” rating and a $43.00 price objective on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, ABIVAX Société Anonyme presently has an average rating of “Moderate Buy” and a consensus price target of $36.50.

ABIVAX Société Anonyme Price Performance

ABVX stock opened at $11.02 on Friday. The stock’s 50 day simple moving average is $12.68 and its 200 day simple moving average is $13.57. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.23. ABIVAX Société Anonyme has a 12-month low of $7.99 and a 12-month high of $17.02.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new stake in ABIVAX Société Anonyme during the first quarter valued at approximately $81,000. Capstone Investment Advisors LLC bought a new stake in shares of ABIVAX Société Anonyme during the 4th quarter valued at $618,000. Ghisallo Capital Management LLC bought a new position in ABIVAX Société Anonyme in the 4th quarter worth $642,000. Kennedy Capital Management LLC lifted its position in ABIVAX Société Anonyme by 35.3% during the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after purchasing an additional 31,331 shares in the last quarter. Finally, Rosalind Advisors Inc. purchased a new position in ABIVAX Société Anonyme during the first quarter valued at $5,411,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.